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Abstract
Introduction: HIV-1 infection leads to chronic inflammation and to an increased risk of non-AIDS mortality. Our objective was
to determine whether AIDS-defining events (ADEs) were associated with increased overall and cause-specific non-AIDS
related mortality after antiretroviral therapy (ART) initiation.
Methods: We included HIV treatment-na€ıve adults from the Antiretroviral Therapy Cohort Collaboration (ART-CC) who initi-
ated ART from 1996 to 2014. Causes of death were assigned using the Coding Causes of Death in HIV (CoDe) protocol. The
adjusted hazard ratio (aHR) for overall and cause-specific non-AIDS mortality among those with an ADE (all ADEs, tuberculosis
(TB), Pneumocystis jiroveci pneumonia (PJP), and non-Hodgkin’s lymphoma (NHL)) compared to those without an ADE was esti-
mated using a marginal structural model.
Results: The adjusted hazard of overall non-AIDS mortality was higher among those with any ADE compared to those
without any ADE (aHR 2.21, 95% confidence interval (CI) 2.00 to 2.43). The adjusted hazard of each of the cause-specific
non-AIDS related deaths were higher among those with any ADE compared to those without, except metabolic deaths
(malignancy aHR 2.59 (95% CI 2.13 to 3.14), accident/suicide/overdose aHR 1.37 (95% CI 1.05 to 1.79), cardiovascular
aHR 1.95 (95% CI 1.54 to 2.48), infection aHR (95% CI 1.68 to 2.81), hepatic aHR 2.09 (95% CI 1.61 to 2.72), respira-
tory aHR 4.28 (95% CI 2.67 to 6.88), renal aHR 5.81 (95% CI 2.69 to 12.56) and central nervous aHR 1.53 (95% CI 1.18
to 5.44)). The risk of overall and cause-specific non-AIDS mortality differed depending on the specific ADE of interest
(TB, PJP, NHL).
Conclusions: In this large multi-centre cohort collaboration with standardized assignment of causes of death, non-AIDS mor-
tality was twice as high among patients with an ADE compared to without an ADE. However, non-AIDS related mortality after
an ADE depended on the ADE of interest. Although there may be unmeasured confounders, these findings suggest that a
common pathway may be independently driving both ADEs and NADE mortality. While prevention of ADEs may reduce subse-
quent death due to NADEs following ART initiation, modification of risk factors for NADE mortality remains important after
ADE survival.
Keywords: AIDS-defining events; non-AIDS mortality; tuberculosis; Pneumocystis jiroveci pneumonia; non-Hodgkin’s lymphoma;
marginal structural model
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1 | INTRODUCTION
In the era of antiretroviral therapy (ART), there have been
striking decreases in acquired immune deficiency syndrome
(AIDS)-related mortality [1–3] and prolongation of life expec-
tancy [4–7] for people living with HIV infection (PLWH). With
this, there has been a shift in distribution of causes of death
toward non-AIDS-defining events (NADEs) [8–12]. Factors
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contributing to non-AIDS mortality include immunodeficiency
[13,14], ART toxicity [15,16], increasing age [17–22], and life-
style factors such as tobacco use and obesity [18,21,23]. How-
ever, chronic inflammation and immune activation produced by
chronic HIV infection as well as many AIDS-defining events
(ADEs) are now recognized as significant drivers in the patho-
genesis of non-AIDS-related deaths [14,24–28].
A previous Antiretroviral Therapy Cohort Collaboration
(ART-CC) study sought to examine variation in mortality asso-
ciated with specific ADEs among patients receiving ART. The
study found that overall mortality rates after an ADE were
dependent on the specific ADE diagnosis and a classification
scheme for ADE severity (mild, moderate, severe) was pro-
posed [29]. This study demonstrated that not all ADEs have
the same consequences with regards to overall mortality.
However, studies to determine if this finding holds true for
mortality due to non-AIDS deaths are lacking.
Our objective was to estimate the overall effect of ADEs as
well as three specific ADEs of differential severity on the risk
of NADE mortality after ART initiation in high-income settings.
We sought to appropriately control for time-updated diagnosis
of ADEs and immune status (CD4+ count and HIV-1 RNA).
Moreover, we evaluated the overall and ADE-specific effects
on differing subtypes of NADE deaths.
2 | METHODS
2.1 | Patient population
We conducted an observational cohort analysis among PLWH
enrolled in the ART-CC from 1996 to 2014 (http://www.b
ris.ac.uk/art-cc) [30]. Data were contributed by 19 cohorts in
Europe and North America. Patients were included if they
were ART-na€ıve, had CD4+ and HIV-1 RNA values available at
ART initiation, and were ≥18 years of age at ART initiation.
Ethics approval was obtained from all participating study sites,
the National Health Service Health Research Authority South
West-Cornwall and Plymouth Research Ethics Committee,
United Kingdom (REC reference 12/SW/0253). Informed con-
sent or a waiver of informed consent were obtained as
required by local site ethics committees. Patients were
assigned a random study number at the local sites and a lim-
ited dataset was transmitted to the ART-CC Data Coordinat-
ing Center.
2.2 | Study definitions
Person-time was contributed beginning at ART initiation
(study baseline) until the earliest of loss to follow-up, death,
or administrative censoring (May 2012 to December 2015,
depending on cohort). ART was defined as a regimen that con-
tained ≥3 drugs including nucleoside reverse transcriptase
inhibitors (NRTIs), protease inhibitors (PIs), non-nucleoside
reverse transcriptase inhibitors (NNRTIs), or integrase inhibi-
tors. Baseline CD4+ and HIV-1 RNA values were defined as
the first value <90 days before or <7 days after ART initia-
tion. Loss to follow-up (LTFU) was defined as >12 months
between available laboratory results; these patients were cen-
sored at 12 months after the date of their last results. Per-
sons were not allowed to re-enter the analysis after meeting
LTFU criteria.
Information on cause of death was recorded using the
International Classification of Diseases Ninth Revision (ICD-9)
code, the ICD-Tenth Revision (ICD-10) code, a classification
based on the Coding of Death in HIV (CoDe) project (http://
www.cphiv.dk/Tools-Standards/CoDe/About), or free text.
Causes of death were classified using an adapted version of
the CoDe protocol into mutually exclusive categories. Clini-
cians classified deaths using information on death (ICD-9/
ICD-10 codes or free text), patient characteristics at ART initi-
ation (age, sex, HIV transmission risk group, ADEs, and hepati-
tis C status), time from ART initiation to death, ADEs after
starting ART, latest CD4 (within six months of death), and
whether a patient was on ART at the time of death. A com-
puter algorithm and a clinician classified deaths using ICD
codes when these codes were available. Otherwise, two clini-
cians independently classified each death. Disagreements
between clinicians and/or computer-classifications were
resolved via panel discussion as per the CoDe protocol [1,31].
The exposure of interest was an ADE after ART initiation,
defined according to the US Centers for Disease Control and
Prevention [32]. Diagnosis of ADEs after ART initiation and
the dates of diagnosis were validated by local site investiga-
tors. In addition to evaluating ADEs overall, two mild ADEs
(tuberculosis (TB) and Pneumocystis jiroveci pneumonia (PJP))
and one severe ADE (non-Hodgkin’s lymphoma (NHL)) accord-
ing a previous classification scheme [29], were evaluated
to elucidate differences in NADE mortality based on ADE
severity.
The outcome of interest was NADE mortality. We evaluated
both overall non-AIDS deaths as well as cause-specific non-
AIDS deaths, including cardiovascular, hepatic, metabolic, non-
AIDS malignancy, non-AIDS infection, renal, respiratory, central
nervous, accident/suicide/overdose, and other NADE deaths
not falling into one of the previous categories.
2.3 | Statistical analysis
For continuous variables, median and interquartile range (IQR)
are shown. For categorical variables, number (n) and percent
(%) are shown. Crude NADE mortality rates per 1000 person-
years (p-y) of follow-up were calculated for the overall popula-
tion as well as for persons with ADE and without an ADE
after ART initiation.
To model the association between ADEs and NADE
mortality while appropriately adjusting for baseline and time-
dependent confounders, marginal structural models were con-
structed [33]. Patient exposure status was assessed monthly
until censoring or death. Patients were classified as unexposed
for each month prior to their first ADE after ART initiation
and exposed in each subsequent month. As we were inter-
ested in ADEs after ART initiation, patients with an ADE prior
to ART initiation were classified as unexposed at baseline.
Inverse probability weights (IPW) for the primary model of
interest were determined based on four components. Each
component was a pooled logistic regression model predicting
probability of the following events each month: 1) ADE diag-
nosis; 2) LTFU; 3) administrative censoring; 4) a competing
event, including death due to other NADEs (in the case of
cause-specific NADE deaths), death due to ADEs, and death
from unknown causes. These models included time since ART
initiation, age at ART initiation, sex, cohort, year of ART
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initiation, baseline ART regimen (PI-based, NNRTI-based,
other), HIV transmission risk group (heterosexual, men who
have sex with men (MSM), injection drug use (IDU), blood
transfusion, other/unknown), presence of ADE at or prior to
ART initiation, baseline CD4+ count, baseline HIV-1 RNA, and
current CD4+ count and HIV-1 RNA; restricted cubic splines
were used for all continuous variables. Both current CD4+
count and HIV-1 RNA were time-dependent variables. If a
patient had more than one measurement during a given
month, the value from the latest date was utilized; if a patient
did not have a measurement during a given month, the value
from the previous month was carried forward.
A weighted pooled logistic regression model including
robust standard errors was used to estimate the hazard ratio
(HR) for NADE mortality comparing those who did and did
not experience the ADE. This weighted pooled logistic regres-
sion model approximates a marginal structural Cox regression
model when certain conditions are met (short intervals and
low event rates) [33,34]. The weights from the four compo-
nents above were multiplied to obtain the single time-updated
weight incorporated into this model. This model included cur-
rent ADE status (current or previous ADE diagnosis), time
since initial visit date in months, age at ART initiation, sex,
cohort, year of ART initiation, baseline ART regimen, HIV
transmission risk factor, presence of ADE at or prior to ART
initiation, baseline CD4+ count, and baseline HIV-1 RNA.
Results are reported with stabilized weights [33] truncated at
the 1st and 99th percentiles. The median of the untruncated
stabilized weights was 0.98 (IQR 0.90 to 1.02) for the model
including all ADEs as the exposure; weights for models corre-
sponding to specific ADE exposures were similar (results not
shown).
In a sensitivity analysis, we fitted several alternative models
of the association between ADEs and non-AIDS mortality,
including an unadjusted model that did not adjust for any
covariates and a model that only adjusted for baseline covari-
ates. For both models, we did not include any IPW and thus
did not account for time-dependent covariates. We also re-
fitted the marginal structural model after excluding observa-
tions from sites with >50% missing codes of death, after
excluding those with AIDS at or prior to baseline, and after
limiting the cohort to only patients with a baseline CD4+
count above 500 cells/mm3. All statistical tests were two-
sided. Statistical analyses were performed using R version 3.2.
Analysis code is available at http://biostat.mc.vanderbilt.edu/
ArchivedAnalyses.
3 | RESULTS
There were 124,587 patients included and followed up for a
total of 770,259 p-y (median 5.18 years) in this study. The
median age at ART initiation was 38 years, 76% were male,
and 12% reported IDU as an HIV transmission factor. The
median baseline CD4+ count was 244 cells/mm3 (IQR 117 to
369 cells/mm3) and the median baseline HIV-1 RNA was
66,580 copies/ml (IQR: 14,000 to 200,000 copies/ml)
(Table 1). There were 14,245 patients (11%) who developed
at least one ADE after ART initiation. Of these, 2174 (15%)
had TB, 1864 (13%) had PJP, and 939 (7%) had NHL (patients
could contribute to >1 ADE category). Among patients with
an ADE, 6588 (46.2%) were on a PI-based regimen, 3955
(27.8%) were on an NNRTI-based regimen, 1114 (7.8%) were
another regimen, and 2588 (18.2%) were not on ART at the
time of the ADE. The proportion of patients with an ADE after
ART initiation was higher among patients with a baseline a
CD4+ count less than 500 cells/ml3 (13,324/110,412; 12.1%)
compared to those with a baseline CD4+ count greater than
500 cells/ml3 (921/14,175; 6.5%).
There were 11,280 deaths during the study period; 2661
(24%) were AIDS-related deaths, 4051 (36%) were non-AIDS
related deaths, and 4568 (40%) were unknown types of
deaths. Among non-AIDS related deaths, 956 (24%) were due
to a non-AIDS malignancy, 673 (17%) were due to accident/
suicide/overdose, 649 (16%) were due to cardiovascular dis-
ease, 598 (15%) were non-AIDS infection, 529 (13%) were
hepatic, 121 (3%) were respiratory, 68 (2%) were renal, 41
(1%) were metabolic, 57 (1%) were central nervous system
(CNS) and 359 (9%) were due to other causes (Table 2). The
proportion of missing death codes varied by cohort (10% to
92%) (Table S1). Among those who died, death codes were
missing for 41% of persons without an ADE after ART initia-
tion compared to 39% of persons with an ADE after ART initi-
ation (p=0.03).
The crude overall non-AIDS mortality rate was 5.26/
1000 p-y (95% confidence interval (CI) 5.09 to 5.42). Persons
with any ADE after ART initiation had a higher crude overall
non-AIDS mortality rate (14.90/1000 p-y (95% CI 13.99 to
15.79)) compared to persons without any ADE after ART initi-
ation (4.28/1000 p-y (95% CI 4.12 to 4.43)). This finding of a
Table 1. Demographic characteristics of the study population,
ART-CC
Overall (N=124,587)
Age (years)-median (IQR) 38 (32 to 46)
Male sex 95,001 (76%)
Year of ART initiation-median (IQR) 2005 (2001 to 2009)
Baseline ART regimen
NNRTI 49,936 (40%)
PI 64,306 (52%)
Other 10,345 (8%)
ADE at or prior to baseline 24,849 (20%)
Transmission risk
Heterosexual 43,644 (35%)
MSM 43,387 (35%)
IDU 15,347 (12%)
Blood transfusion 980 (1%)
Other/unknown 21,229 (17%)
Baseline CD4+ count (cells/ml),
median (IQR)
244 (117 to 369)
Baseline HIV-1 RNA (copies/ml),
median (IQR)
66,580 (14,000 to 200,000)
Years of follow-up, median (IQR) 5.18 (2.28 to 9.42)
ADE, AIDS-Defining Event; IQR, interquartile range; ART, antiretrovi-
ral therapy; PI, protease inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; HIV, human immunodeficiency virus; MSM,
male-male sexual contact; IDU, injection drug use; ml, millilitre.
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higher crude overall non-AIDS mortality rate held true for
each of the specific ADEs evaluated (Table 3). The median
time from diagnosis of any ADE after ART initiation to NADE
mortality was 702 days (IQR: 147 to 1661 days). This time
from ADE to NADE mortality for the three specific ADEs of
interest was 902 days for TB (IQR: 377 to 1912 days),
568 days for PJP (IQR 170 to 1413 days) and 225 days for
NHL (IQR 89 to 1534 days).
In the marginal structural model which adjusted for time-
updated covariates, the adjusted hazard of death due to any
NADE was significantly higher among patients with any ADE
after ART initiation (adjusted hazard ratio (aHR) 2.21, 95% CI
2.00 to 2.43) compared to patients without any ADE after
ART initiation. This finding was true for overall NADE deaths
and for each NADE death category except for metabolic
NADE deaths. The association of cause-specific NADE mortal-
ity differed depending on the specific ADE of interest. TB was
associated with a higher risk of cardiovascular, metabolic, and
non-AIDS infection NADE mortality. PJP was associated with a
higher risk of non-AIDS infection, respiratory and accident/sui-
cide/overdose NADE deaths. NHL was associated with a
higher risk of renal NADE deaths. All three ADEs (TB, PJP
and NHL) were associated with a higher risk of death due to
non-AIDS malignancies (Table 4).
The results from the marginal structural model were some-
what attenuated although largely unchanged when compared
to the results of the unadjusted model with a hazard ratio of
3.50 (95% CI 3.26 to 3.75) for death due to any NADE
among patients with any ADE after ART initiation compared
to patients without any ADE after ART initiation (Table S2).
Similarly, in the model adjusted only for baseline covariates
the adjusted ratio for death due to any NADE was 2.68 (95%
CI 2.47 to 2.90) among patients with any ADE after ART initi-
ation compared to patients without any ADE after ART initia-
tion (Table S3).
The results of sensitivity analyses with alternative exclusion
criteria as described in the methods were largely unchanged
as well. In the model excluding all sites with >50% missing
codes of death (Table 5), the aHR for death due to any NADE
was 2.23 (95% CI 1.97 to 2.53). In the model excluding those
individuals with ADEs at or prior to baseline (Table S4), the
aHR for death due to any NADE was 2.37 (95% CI 2.10 to
2.67). Notably, among 14,175 (11%) patients in this cohort
with a baseline CD4 cell count >500 cells/ml3, the aHR for
overall NADE mortality following any ADE was 2.66 (95% CI
1.84 to 3.87).
4 | DISCUSSION
In this large, multi-centre cohort collaboration with standard-
ized assignment of causes of death, the risk of death due to
NADEs overall was over two times higher for patients with
any ADE after ART initiation compared to without an ADE fol-
lowing ART initiation. This finding held true for each of the
three selected individual ADEs (TB, PJP and NHL). However,
there was heterogeneity in the risk of cause-specific NADE
mortality across the individual ADEs evaluated, consistent
with previous studies of all-cause mortality. These findings
suggest that prevention of ADEs, perhaps with more frequent
HIV testing and early treatment with ART as recommended
by current guidelines, may decrease subsequent NADE
mortality.
Overall, the crude mortality rate per 1000 p-y due to
NADEs (5.26 (95% CI 5.09 to 5.42)) was slightly higher than
that reported from other cohorts in high-income countries,
including South Korea (3.71, 95% CI 2.52 to 5.48) [35], Spain
(3.75, 95% CI 2.84 to 4.94) [36], and from the Data collection
on Adverse Events of anti-HIV Drugs (D:A:D) cohort in
Table 2. Classification of deaths, ART-CC
CoDe* codes Number (%)
AIDS coded deaths 2661 (24%)
AIDS infection 01.1 1036
AIDS malignancy 01.2 635
AIDS unspecified 01 990
NADE coded deaths 4051 (36%)
Non-AIDS malignancy 04 956
Accident/suicide/overdose 16, 17, 19 673
Cardiovascular 08, 09, 12, 24 649
Non-AIDS infection 02 598
Hepatic 03, 14 529
Respiratory 13, 25 121
Renal 15 68
Central nervous 23 57
Metabolic 05, 06, 07 41
Other 10, 11, 18, 20, 22,
26, 27, 28, 29, 90
359
Unknown death 4568 (40%)
Coded, unknown 91, 92 1253
Uncoded (no information) 3315
Total deaths 11,280
*Coding of Death in HIV (CoDe) project (http://www.cphiv.dk/Tools-
Standards/CoDe/About). AIDS, acquired immunodeficiency syndrome;
NADE, non-AIDS-defining event.
Table 3. Crude non-AIDS related mortality rate per 1000 person-
years, ART-CC
NADE
deaths
Follow-up
(years)
NADE mortality
rate per 1000
person-years (95% CI)
Overall 4051 770,259 5.26 (5.09 to 5.42)
Persons with ADE 1057 70,917 14.88 (13.99 to 15.79)
Persons without ADE 2994 699,342 4.28 (4.12 to 4.43)
Persons with TB 131 11,587 11.17 (9.28 to 13.07)
Persons without TB 3920 758,573 5.17 (5.00 to 5.32)
Persons with PJP 129 8247 15.62 (13.05 to 18.44)
Persons without PJP 3922 762,013 5.15 (4.98 to 5.30)
Persons with NHL 44 2886 15.12 (10.88 to 20.02)
Persons without NHL 4007 767,373 5.22 (5.05 to 5.38)
NADE, non-AIDS defining event; ADE, AIDS-defining event; CI, confi-
dence interval; TB, tuberculosis; PJP, Pneumocystis jiroveci pneumonia;
NHL, non-Hodgkin’s lymphoma.
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Australia, Europe, and the United States (4.28, 95% CI 4.06
to 4.53) [12,37]–the latter two have some overlap with our
dataset. It is possible this finding is related to differences in
baseline CD4+ count (342 cells/mm3 (IQR 163 to 546) in
Spain, 400 (IQR 242 to 590) in D:A:D, and 244 (IQR 116 to
369) for ART-CC, respectively) as several previous studies
have described lower CD4+ counts as risk factors for NADE
mortality [13,14]. In addition, there may be background differ-
ences in NADE prevalence and NADE risk factors within the
study populations as well as changes in these populations over
time.
Over 60% of the coded causes of death in ART-CC were
due to NADEs. This is consistent with the findings from a
recent systematic review and meta-analysis which estimated
the pooled proportion of patients with death due to NADEs in
high-income countries during the ART era was 54% (95% CI
46% to 62%) [37]. The most frequent cause of NADE death in
our study was non-AIDS malignancies (24%) followed by acci-
dents/suicides/overdoses (17%), cardiovascular deaths (16%),
non-AIDS infections (15%) and hepatic deaths (13%). These
cause-specific findings are also consistent with this recent sys-
tematic review and meta-analysis (non-AIDS malignancies 28%
(95% CI 23% to 33%), cardiovascular deaths 15% (95% CI
13% to 17%), non-AIDS infections 10% (95% CI 6% to 14%)
and hepatic deaths 14% (95% CI 10% to 19%)) [37]. Pooled
findings for accidents (n=187; 28%), suicides (n=180; 27%)
Table 4. Adjusted marginal structural models for hazard ratios of cause-specific mortality
Type of death
N=6712
coded deaths
aHR (95% CI)
Tuberculosis
aHR (95% CI)
Pneumocystis
aHR (95% CI)
Non-Hodgkin Lymphoma
aHR (95% CI)
All ADEs
ADEs 2661 2.65 (2.20 to 3.19) 5.10 (4.36 to 5.97) 29.49 (25.48 to 34.13) 7.51 (6.64 to 8.49)
NADEs 4051 1.68 (1.38 to 2.04) 2.21 (1.78 to 2.73) 2.95 (2.12 to 4.10) 2.21 (2.00 to 2.43)
NADE malignancy 956 1.84 (1.23 to 2.76) 2.12 (1.30 to 3.47) 5.63 (3.46 to 9.16) 2.59 (2.13 to 3.14)
Accident, suicide, overdose 673 1.39 (0.81 to 2.38) 2.60 (1.54 to 4.38) 2.37 (0.90 to 6.26) 1.37 (1.05 to 1.79)
Cardiovascular 649 1.88 (1.15 to 3.08) 1.74 (0.96 to 3.15) 0.95 (0.20 to 4.46) 1.95 (1.54 to 2.48)
NADE infection 598 1.63 (1.05 to 2.54) 2.66 (1.74 to 4.06) 1.57 (0.45 to 5.47) 2.17 (1.68 to 2.81)
Hepatic 529 1.36 (0.77 to 2.40) 1.06 (0.52 to 2.19) 2.48 (0.79 to 7.76) 2.09 (1.61 to 2.72)
Respiratory 121 0.85 (0.24 to 2.92) 6.76 (3.03 to 15.09) 1.78 (0.44 to 7.16) 4.28 (2.67 to 6.88)
Renal 68 3.13 (0.88 to 11.19) 0.95 (0.22 to 4.05) 9.31 (2.25 to 38.45) 5.81 (2.69 to 12.56)
Central nervous 57 0.74 (0.10 to 5.47) 0.66 (0.09 to 5.04) a 2.53 (1.18 to 5.44)
Metabolic 41 4.30 (1.35 to 13.69) a a 1.53 (0.67 to 3.47)
NADE, other 359 1.77 (0.86 to 3.66) 3.20 (1.40 to 7.30) 2.45 (0.96 to 6.25) 2.98 (2.14 to 4.16)
aDenotes that no deaths occurred in these categories.
+Models were adjusted for baseline CD4+ count, baseline HIV-1 RNA, sex, HIV transmission risk group, age, calendar year of ART initiation, base-
line ART regimen (PI/NNRTI/other), ADE at or prior to the time of enrolment, and ART-CC cohort.
Table 5. Adjusted marginal structural models for hazard ratios of cause-specific mortality (excluding all sites with >50% missing
codes of death)
Type of death
N=4,664
coded deaths
aHR (95% CI)
tuberculosis
aHR (95% CI)
pneumocystis
aHR (95% CI)
non-Hodgkin lymphoma
aHR (95% CI)
All ADEs
ADEs 1841 3.34 (2.64 to 4.23) 7.48 (6.06 to 9.23) 31.23 (26.83 to 36.36) 9.24 (8.08 to 10.58)
All NADEs 2823 1.82 (1.41 to 2.36) 1.58 (1.14 to 2.18) 2.48 (1.74 to 3.53) 2.23 (1.97 to 2.53)
NADE malignancy 674 1.86 (1.10 to 3.15) 0.70 (0.22 to 2.18) 3.68 (2.10 to 6.46) 2.14 (1.65 to 2.77)
Accident, Suicide, Overdose 491 0.87 (0.33 to 2.31) 1.18 (0.50 to 2.81) 2.57 (0.98 to 6.72) 1.14 (0.78 to 1.67)
Cardiovascular 413 2.90 (1.57 to 5.36) 0.99 (0.41 to 2.40) 1.02 (0.23 to 4.64) 2.11 (1.50 to 2.96)
Hepatic 384 1.06 (0.52 to 2.19) 1.08 (0.45 to 2.63) 1.70 (0.42 to 6.83) 1.83 (1.31 to 2.57)
NADE infection 352 2.03 (1.09 to 3.77) 3.01 (1.69 to 5.37) 1.70 (0.49 to 5.98) 2.50 (1.76 to 3.54)
Respiratory 98 1.70 (0.50 to 5.80) 4.81 (2.02 to 11.43) 2.02 (0.50 to 8.08) 4.72 (2.86 to 7.80)
Renal 52 5.03 (1.41 to 17.94) 1.23 (0.16 to 9.28) 10.00 (2.51 to 39.88) 9.19 (4.03 to 20.97)
Central nervous 47 1.11 (0.15 to 8.12) 1.31 (0.17 to 10.20) a 2.52 (1.15 to 5.50)
Metabolic 28 1.57 (0.20 to 12.36) a a 1.47 (0.54 to 3.99)
NADE, other 284 2.09 (0.93 to 4.71) 3.11 (1.16 to 8.32) 2.75 (1.07 to 7.07) 3.16 (2.18 to 4.57)
aDenotes that no deaths occurred in these categories.
+Models were adjusted for baseline CD4+ count, baseline HIV-1 RNA, sex, HIV transmission risk group, age, calendar year of ART initiation, base-
line ART regimen (PI/NNRTI/other), ADE at or prior to the time of enrolment, and ART-CC cohort.
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and overdoses (n=306; 45%) were not reported although
these types of deaths were the second most common NADE
death in our population.
A previous study conducted within the ART-CC found that
overall mortality rates (deaths due to both ADEs and NADEs)
subsequent to an ADE were dependent on the specific ADE
diagnosis; NHL was classified as severe and TB and PJP were
classified as mild [29]. In this study, while the associations
between specific ADEs and overall NADE mortality were all
statistically significant, we note that the strength of that asso-
ciation varied. The point estimate for the risk of NADE mortal-
ity overall was highest for NHL (2.95, 95% CI 2.12 to 4.10),
previously designated as a severe ADE [29].
However, the risk of cause-specific NADE mortality differed
between the three ADEs evaluated (TB, PJP, and NHL). For
example, only TB was associated with cardiovascular NADE
deaths. Previous epidemiologic studies have described an
association between TB and cardiovascular disease. A large
retrospective study in Taiwan reported a 40% increased risk
of cardiovascular events among patients with TB compared to
patients without TB after controlling for important co-morbid-
ities [38]. Several possible mechanisms of the association
include direct mycobacterial tissue invasion, auto-immunity
mediated by antibodies against mycobacteria, as well as
increased inflammation and immune activation, [39], although
prospective studies are needed.
Only PJP was associated with subsequent death due to respi-
ratory events and accident/suicide/overdoses. In the Pulmonary
Complications of HIV Study, PJP was associated with declines in
lung function that persisted even after the acute infection
resolved [40]. However, the association of PJP with accidents/
suicides/overdoses suggests that not all of these associations
may be mechanistic and that unmeasured confounders such as
mental illness and alcohol/drug use are likely important.
There are some limitations to this study. First, there are
likely unmeasured confounders not accounted for in these
analyses. The ART-CC does not collect information on other
important lifestyle factors such as tobacco use, alcohol use,
active IDU and body mass index (BMI). PLWH who smoke
have higher rates of cardiovascular disease, respiratory dis-
ease and malignancies than people without HIV infection who
smoke. A recent modelling study showed that PLWH in the
US who smoke lose as much or more life expectancy from
smoking than from HIV infection itself. Moreover, this study
showed that smoking cessation would result in a greater gain
in life expectancy than early HIV testing and treatment or
improved ART adherence [41]. It is unclear if the associations
we found would remain after controlling for such potentially
important unmeasured variables.
Second, it is possible that some causes of death may be
coded inaccurately as the coding was performed retrospec-
tively without access to complete medical histories. It is also
possible that we categorized diseases of different aetiologies
in the same cause-specific categories. For example, it is possi-
ble that a dysrhythmia due to ischemic heart disease and a
dysrhythmia due to drug overdose may have both been cate-
gorized as a cardiovascular cause of death. However, given
the rigorous standardized process used for coding of deaths it
is likely that the majority were coded correctly. Moreover,
some deaths could not be coded and therefore some deaths
due to NADEs may have been missed.
Thirdly, cause of death was not available for 40% of deaths
within the cohort over the study period. Therefore, we per-
formed a sensitivity analysis in which we excluded all sites with
>50% missing codes of death. Compared to the main results,
the results of the sensitivity analysis were largely unchanged.
However, causes of death in the main analysis were differen-
tially missing between those with and without ADEs after ART
initiation, which may have led to biased results.
5 | CONCLUSIONS
In conclusion, in this cohort of persons initiating ART, NADE
mortality rates were higher among those with an ADE after
ART initiation compared to those without an ADE after ART
initiation. Consistent with previous studies of overall mortality,
NADE mortality rates after an ADE depended on the specific
ADE diagnosed. Although there may be unmeasured con-
founders and associations may not be mechanistic, these find-
ings suggest that a common pathway may be independently
driving both ADEs and NADE mortality. ADE prevention, per-
haps by more frequent HIV testing and initiating treatment at
higher CD4+ counts, as well as the continued modification of
risk factors such as tobacco use, may reduce subsequent
NADE mortality. In addition, these findings underscore the
need for future studies to elucidate a potential mechanism for
this association, including that of chronic inflammation and
immune activation due to ADEs. In these future studies it will
be important to address potential confounders including
important modifiable lifestyle factors such as tobacco use.
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